Relmada Therapeutics Files 8-K Report
Ticker: RLMD · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-statements
TL;DR
Relmada Therapeutics filed a routine 8-K, standard corporate update.
AI Summary
On December 9, 2024, Relmada Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of a corporate event and includes financial statements and exhibits. No specific material events or financial figures beyond standard reporting requirements were detailed in the provided text.
Why It Matters
This 8-K filing indicates that Relmada Therapeutics, Inc. is fulfilling its regulatory reporting obligations, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report, indicating routine corporate disclosures rather than a specific material event that would inherently increase risk.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- December 9, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-39082 (identifier) — Commission File Number
- 45-5401931 (identifier) — IRS Employer Identification No.
- 2222 Ponce de Leon Blvd. , Floor 3 Coral Gables , FL 33134 (address) — Address of principal executive offices
- ( 212 ) 547-9591 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Relmada Therapeutics, Inc.?
The primary purpose of this 8-K filing is to serve as a current report, notifying the SEC of corporate events and including financial statements and exhibits as required.
On what date was this 8-K report filed or reported as of?
The report was filed as of December 9, 2024, and the date of the earliest event reported is also December 9, 2024.
What is Relmada Therapeutics, Inc.'s state of incorporation and commission file number?
Relmada Therapeutics, Inc. is incorporated in Nevada and its commission file number is 001-39082.
What is the principal executive office address for Relmada Therapeutics, Inc.?
The principal executive office address is 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
Does the filing indicate any specific new material events or financial performance details?
Based on the provided text, the filing is a standard 8-K current report and does not detail specific new material events or financial performance beyond the requirement to include financial statements and exhibits.
Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-12-09 07:49:36
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The Nasdaq
Filing Documents
- ea0224026-8k_relmada.htm (8-K) — 27KB
- ea022402601ex99-1_relmada.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 17KB
- 0001213900-24-106646.txt ( ) — 235KB
- rlmd-20241209.xsd (EX-101.SCH) — 3KB
- rlmd-20241209_lab.xml (EX-101.LAB) — 33KB
- rlmd-20241209_pre.xml (EX-101.PRE) — 22KB
- ea0224026-8k_relmada_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 9, 2024, Relmada Therapeutics, Inc. (the "Company") issued a press release announcing that in light of the recent data monitoring committee (DMC) evaluation of the full dataset from the Reliance II Phase 3 study of the Company's REL-1017 program, the Company will discontinue the Reliance II and Relight Phase 3 studies, and has commenced a process to explore strategic alternatives to maximize shareholder value. The Company will continue to advance the Phase 1 study of REL-P11, an investigational agent for the treatment of metabolic disease. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued on December 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 9, 2024 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2